• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Reliever-triggered inhaled glucocorticoid therapy in among Black and Latinx adults with asthma

byDavid XiangandHarsh Shah
March 9, 2022
in Chronic Disease, Public Health, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Provision of an inhaled glucocorticoid and instruction on its use led to a significantly lower rate of severe asthma exacerbations among Black and Latinx adults with asthma.

2. Provision of an inhaled glucocorticoid and instruction on its use increased monthly asthma control.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Black and Latinx populations in the United States bear disproportionate asthma morbidity and mortality. Asthma-related emergency department visits and hospitalizations are higher among Black and Latinx persons than among White persons. Mortality from asthma is also twice as high among Black and Latinx persons compared to White persons. While current recommendations include the use of inhaled glucocorticoids for asthma-controller therapy, there is a gap in knowledge as to understanding the effectiveness of this strategy among Black and Latinx patients, as few trials have included substantial proportions of these populations. This study found that providing an as-needed glucocorticoid inhaler and one-time instruction on its use significantly decreased severe asthma exacerbations among Black and Latinx adults with asthma. This study was limited by being open-label and the possibility of a placebo effect, as well as the study population including many different ethnic groups and women being overrepresented in this trial. Nevertheless, these study’s findings are significant, as they demonstrate that the provision of inhaled glucocorticoids with instruction for use significantly reduced the risk of severe asthma exacerbations among Black and Latinx patients with moderate to severe asthma.

Click to read the study in NEJM

Relevant Reading: Biologic Therapies for Severe Asthma

In-Depth [open-label randomized trial]: This pragmatic, open-label trial randomly assigned Black and Latinx patients with moderate-to-severe asthma to receive either patient-activated reliever-triggered inhaled glucocorticoids plus usual care or to continue their usual care. There were 1201 adults (603 Black and 598 Latinx) in the trial, with 600 assigned to the intervention group and 601 to the usual-care group. Patients who were aged 18 to 75 with clinician-diagnosed asthma and self-identified as Black or Latinx were included in the study. Patients who were taking regular systemic glucocorticoids were excluded from the study. The primary outcome was the annualized rate of severe asthma exacerbations. Outcomes in the primary analysis were assessed via Andersen-Gill adaption of the time-to-event Cox proportional-hazards model with stratification according to race and ethnic group and adjustment for baseline characteristics. Based on the analysis, the annualized rate of severe asthma exacerbations was 0.69 (95% confidence interval [CI], 0.61 to 0.78) in the inhaled glucocorticoid group and 0.82 (95% CI, 0.73 to 0.92) in the usual-care group. To measure monthly asthma control, the study utilized the Asthma Control Test (ACT), with a range from 5 (poor) to 25 (complete control). The study found that ACT scores increased by 3.4 points (95% CI, 3.1 to 3.6) in the intervention group and 2.5 points (95% CI, 2.3 to 2.8) in the usual-care group. Additionally, to quantify the quality of life, the study utilized the Asthma Symptom Utility Index (ASUI, range of 0 to 1 with lower scores indicating greater impairment and lower quality). The results demonstrate that the ASUI scores for the intervention group increased by 0.12 points (95% CI, 0.11 to 0.13) compared to increasing by 0.08 points in the usual-care group (95% CI, 0.07 to 0.09). Overall, this study demonstrated that instruction and provision of reliever-triggered inhaled glucocorticoids among Black and Latinx populations with moderate-to-severe asthma can reduce the risk of severe asthma exacerbations, providing a new strategy to reduce disparities in asthma morbidity.

RELATED REPORTS

Oral gefapixant reduces frequency of refractory or unexplained chronic coughs

Hospitalized Covid-19 patients from socially vulnerable neighborhoods have greater illness severity

#VisualAbstract: High-dose glucocorticoids may be detrimental for the management of patients with advanced melanoma expieriencing immune-related adverse events

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: asthmaasthma exacerbationglucocorticoidminoritysevere asthma
Previous Post

Melioidosis outbreak is associated with imported aromatherapy spray

Next Post

#VisualAbstract: No difference in survival between fluorouracil, cisplatin, or carboplatin-based paclitaxel therapy for locally advanced esophageal squamous cell carcinoma

RelatedReports

Masks for personal protection for SARS-CoV-2 infection
Chronic Disease

Oral gefapixant reduces frequency of refractory or unexplained chronic coughs

April 5, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Hospitalized Covid-19 patients from socially vulnerable neighborhoods have greater illness severity

March 20, 2022
#VisualAbstract: High-dose glucocorticoids may be detrimental for the management of patients with advanced melanoma expieriencing immune-related adverse events
StudyGraphics

#VisualAbstract: High-dose glucocorticoids may be detrimental for the management of patients with advanced melanoma expieriencing immune-related adverse events

November 16, 2021
Combination salmeterol-fluticasone therapy noninferior to fluticasone monotherapy for asthma events: The VESTRI trial
Chronic Disease

Itepekimab provides beneficial effects for patients with moderate-to-severe asthma.

November 12, 2021
Next Post
#VisualAbstract: Delayed receipt of adjuvant hormone therapy is associated with worse survival in HR⁺, ERBB2- breast cancer

#VisualAbstract: No difference in survival between fluorouracil, cisplatin, or carboplatin-based paclitaxel therapy for locally advanced esophageal squamous cell carcinoma

Tremor and memory symptoms prior to diagnosis demonstrate the strongest associations with subsequent Parkinson disease

Blindness and visual impairment decreasing worldwide

Faricimab noninferior to aflibercept for treatment of neovascular age-related macular degeneration

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
  • Operating the day after performing surgery the previous night not associated with adverse patient outcomes
  • Gratitude-focused writing may improve mental wellness during periods of chronic stress
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.